BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.61−0.07 (-0.91%)
Close on Nov 13, 2026Market cap $1.94BP/E –Yield –
BioCryst Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
BioCryst Pharmaceuticals's enterprise value was $2.00B on Nov 11, 2026, against $1.49B a year earlier. Over the last 5 years it ranged from $764.08M to $2.71B, with a median of $1.62B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $2.00B | +22.9% |
| 2025 | Dec 31, 2025 | $1.62B | +5.3% |
| 2024 | Dec 31, 2024 | $1.54B | +48.6% |
| 2023 | Dec 29, 2023 | $1.04B | -46.4% |
| 2022 | Dec 30, 2022 | $1.94B | -20.0% |
| 2021 | Dec 31, 2021 | $2.42B | +106.7% |
| 2020 | Dec 31, 2020 | $1.17B | +275.0% |
| 2019 | Dec 31, 2019 | $312.58M | -59.1% |
| 2018 | Dec 31, 2018 | $764.35M | +137.8% |
| 2017 | Dec 29, 2017 | $321.47M | -22.4% |
| 2016 | Dec 30, 2016 | $414.07M | -42.2% |
| 2015 | Dec 31, 2015 | $716.51M | -4.0% |
| 2014 | Dec 31, 2014 | $746.70M | +71.1% |
| 2013 | Dec 31, 2013 | $436.50M | +612.9% |
| 2012 | Dec 31, 2012 | $61.23M | – |
| 2011 | Dec 30, 2011 | -$13.89M | – |
See a number that looks wrong?